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a b s t r a c t
Inﬂuenza infection of humans remains an important public health problem. Vaccine strategies result in a
signiﬁcant but only partial control (65–85%) of infection. Thus, chemotherapeutic approaches are needed
to provide a solution both for vaccine failures and to limit infection in the unvaccinated population.
Previously (Walsh et al., 2011; Teijaro et al., 2011) documented that sphingosine-1-phosphate 1 receptor
(S1P1R) agonists signiﬁcantly protected mice against pathogenic H1N1 inﬂuenza virus by limiting
immunopathologic damage while allowing host control of the infection. Here we extend that observation
by documenting S1P1R agonist can control pathogenic H1N1 inﬂuenza infection in ferrets. S1P1R agonist
was more effective in reducing pulmonary injury than the antiviral drug oseltamivir but, importantly,
combined therapy was signiﬁcantly more effective than either therapy alone.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Newly emerging and re-emerging inﬂuenza virus infections
provide considerable medical, public health, and economic hard-
ships. These viral infections loom as important zoonotic human
diseases with the threat of human-to-human transmission and
excessive high infectivity and mortality rates. In the current
century, the ﬁrst inﬂuenza virus pandemic occurred in 2009,
H1N1 inﬂuenza infection rapidly infected millions worldwide with
estimates exceeding 290,000 deaths (Itoh et al., 2009; Shieh et al.,
2009). In addition, non-pandemic seasonal inﬂuenza viruses cause
approximately 36,000 deaths yearly in the United States. Vaccina-
tion is useful in providing protection of both uninfected (naïve)
or previously vaccinated individuals although the vaccine is only
65–85% effective (www.CDC.gov). Thus, a complementary
approach is required to protect those who do not respond to
vaccination and others who are unvaccinated against a currently
circulating inﬂuenza virus.
The end result of any viral infection reﬂects the balance
between the virulence of the infecting agent and the resistance
of the host. Over time, inﬂuenza virus survival relies on escape
from host resistance through antigenic alteration arising via
genetic drift by point mutations in the viral HA or through
reassortment by genetic shift of its current HA ligand with that
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of viruses retained in non-human animals. The deﬁning event in
host resistance is the efﬁciency and effectiveness of its antiviral
immune response. However, in certain instances the immune
response becomes exaggerated and an over-abundant extreme
innate and adaptive immune response termed “cytokine storm”
leads to immune response-mediated tissue and cellular injury.
Pulmonary injury associated with inﬂuenza virus infection
results from the combined effect of two factors. First, viruses
own intrinsic virulence in lysing cells it infects and, second, the
intensity of the immune response elicited by the virus that itself
also damages tissues and cells. Anti-inﬂuenza drugs like neurami-
nidase inhibitors are effective therapies to diminish ongoing
infections. However, such treatment has a negligible effect on
cytokine storm and exerts selective pressure on viral progeny
promoting their mutation and selection creating a new generation
of inﬂuenza viruses that is more ﬁt and resistant to the antiviral
drug (Poon et al., 2010; Vijaykrishna et al., 2010).
Earlier we provided the ﬁrst deﬁnitive experimental evidence
that cytokine storm rather than being an event accompanying
inﬂuenza infection, by itself, was a major contributor to the
resultant pulmonary injury and hence an important player in the
morbidity and mortality of inﬂuenza virus pathogenesis (Marsolais
et al., 2009; Teijaro et al., 2011; Walsh et al., 2011). Utilizing mice
infected with a non-adapted human pathogenic H1N1 inﬂuenza
2009 viruses we showed that the resultant cytokine storm was
chemically treatable utilizing immunomodulatory small mole-
cules, either sphingosine-1-phosphate (S1P) receptor (R) agonist
that signals through four of the ﬁve S1PR, R1, 3, 4, 5 (Marsolais
et al., 2009; Walsh et al., 2011) or S1P1R speciﬁc agonists (Teijaro
et al., 2011). These immunomodulating molecules dramatically
blunted the production of cytokines/chemokines and the innate
cellular immune response. Such therapies did not alter the host0s
ability to control the viral infection but successfully limited
immunopathologic injury and proved more effective than optimal
therapy with the anti-inﬂuenza neuraminidase drug oseltamivir,
82% vs. 50% protection from mortality (Walsh et al., 2011). More
important, combination therapy with both drugs provided greater
than 96% survival rate (Walsh et al., 2011).
Mice and ferrets are the most useful and productive small
animal models to study inﬂuenza virus pathogenesis. While the
mouse cost is low and provides availability of reagents, well-
deﬁned genetics, and transgenic models, it fails to mimic clinical
signs in humans. Further, its respiratory tract/pulmonary anatomy/
physiology differs from humans and is a poor choice to study virus
transmission. In contrast, ferrets display clinical signs found in
humans following inﬂuenza infection as elevated body tempera-
tures, nasal discharge and sneezing, can transmit infection to both
healthy ferrets and humans, and share similar lung physiology and
patterns of binding to the receptor for the virus that is throughout
the respiratory tract (Belser et al., 2011; Maher and DeStefano,
2004; Smith and Sweet, 1988). Thus, the pathogenesis of inﬂuenza
virus in ferrets more closely resembles that of humans than mice.
Further, the initial transmission and isolation of inﬂuenza from
humans occurred via ferrets with both animal species cross-
transmitting to each other. For these reasons we studied in ferrets
the therapeutic efﬁciency of S1P1R agonist alone and in combina-
tion with high dose of oseltamivir in the pathogenesis of human
pathologic H1N1 inﬂuenza infection. Our results clearly show that
S1P1R agonist was beneﬁcial in altering the clinical course and
was signiﬁcant in blunting the pulmonary injury caused by the
H1N1 inﬂuenza virus. As anticipated S1P1R signaling did not blunt
viral loads in the lung on the third day of infection. Further, as in
the mouse, the combination therapy of the S1P1R agonist which
primarily treats the immune-mediated injury and antiviral neur-
aminidase oseltamivir which controls viral replication, gave the
greatest therapeutic beneﬁt.
Results and discussion
Thirty-ﬁve male ferrets, average weights of 417723 g, were
randomly assigned to one of four groups of eight, or one group of
three animals. On study day 0, all animals in groups comprising
eight ferrets were challenged intranasally with 1106 TCID50 of
pathogenic human A/California/04/09H1N1 inﬂuenza virus. The
group of three ferrets which received no virus were euthanized at
day 0 as controls for tissue analysis (negative control). Of the
ferrets receiving virus, one group received only vehicle (positive
control), a second group received oseltamivir 12.5 mg/kg adminis-
tered orally 2 h following virus inoculation, and then twice a daily on
study days 1 through 5. A third group was treated orally with the
S1P1 receptor agonist RP-002 at 6 mg/kg at 1, 25, and 49 h post-
infection. The fourth group received a combination of RP-002 and
oseltamivir at the same time and dosages listed above. Of the eight
ferrets in each group, four were randomly selected for sacriﬁce at day
3 post-infection for histopathologic examinationwhile the remaining
four ferrets in each group were followed for up to 2 weeks.
Clinical ﬁndings
All ferrets were challenged with human 2009 pandemic inﬂu-
enza virus administered at Battelle due to biosafety concerns.
Observations were measured in eight ferrets per group for the ﬁrst
3 days. At day 3, four ferrets from each group were randomly
selected for euthanasia to obtain tissues for study. Thereafter
clinical ﬁndings were recorded in the four remaining ferrets.
Temperatures (Fig. 1A) were recorded daily at two sites (shoulder
blade and hip) and displayed highest peak at 24 h post-infection.
Ferrets receiving only vehicle recorded temperatures higher than
the other three groups with ferrets receiving only S1P1 receptor
agonist RP-002 or only oseltamivir showing similar temperature
increases that were consistently less than ferrets that received
neither therapy. The smallest increase in temperature occurred
among ferrets that received combined therapy of RP-002 and
oseltamivir. This trend continued throughout the ﬁrst three days of
infection, after which low-grade temperatures persisted until the
termination of the study.
The second quantiﬁable examination was clinical activity and
plotted in Fig. 1B as % activity compared to baseline control. Each
experimental group was studied twice daily from the afternoon
after initiating infection and then each morning. Activity was
recorded as alert and playful, alert but only playful when stimu-
lated, or neither alert nor playful at any time. As shown in Fig. 1B,
for the ﬁrst two and one-half days post-infection, none of the eight
ferrets in any of the four groups displayed a loss of activity. By day
3 post-infection, two of four ferrets treated with vehicle or with
RP-002 lost activity compared to one of four ferrets treated with
oseltamivir. None of the four ferrets given a combination therapy
with RP-002 and oseltamivir exhibited any loss of activity. By day
5 post-infection and thereafter ferrets treated with RP-002 only or
RP-002 combined with oseltamivir displayed no loss of activity.
However at day 5, one out of four infected ferrets treated only with
oseltamivir showed a loss of activity but thereafter activity was
present in all ferrets in this group up to day 12 (data not shown).
By contrast, all ferrets receiving only vehicle appeared ill with only
one of four showing activity on day 4 (data not shown) and none
of the four ferrets in this group displayed activity at days 5 and 6
post-infection. Recovery occurred in the vehicle only treated group
at day 7 post-infection. Body weights were measured day 1, day
0, and every day thereafter and shown in Fig. 1C. There was a slight
loss of weight in ferrets receiving RP-002, oseltamivir, or the
combined RP-002þoseltamivir therapy 24 h after inﬂuenza chal-
lenge, but by day 2 and thereafter, weights in all four experimental
groups increased throughout the observation period.
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In summary, ferrets provided combination therapy of a S1P1
receptor agonist along with antiviral oseltamivir, with the excep-
tion of an elevated temperature on day 1 post-infection, showed
negligible clinical signs resulting from the H1N1 human patho-
genic inﬂuenza virus infection. In contrast, providing infected
ferrets with either S1P1 agonist or the antiviral agent oseltamivir,
while successfully blunting part of the manifestations of the
inﬂuenza infection as recorded by lowered temperatures and less
loss of activity when compared to vehicle only treated ferrets were
not as successful as those receiving the combined therapy. Reasons
for differences in kinetics concerning somnolence with loss of
spontaneous or stimulated activity seen with either S1P1 receptor
agonist or oseltamivir singular therapy is not clear but may reﬂect
differences in blunting of innate immune response in lungs and/or
different kinetics in viral replication or different pharmacologic
side-effects of the drugs. The next series of studies utilized
histopathologic study of lungs of ferrets sacriﬁced at day 3 post-
infection.
Histopathologic ﬁndings
To evaluate the impact of RP-002 or oseltamivir therapy alone
or in combination on ferrets infected with human pandemic
inﬂuenza virus, four ferrets from each of these three groups and
four infected ferrets receiving only vehicle were sacriﬁced three
days post-infection. Pulmonary lobes from each ferret were
studied in terms of upper, lower, and medial areas with at least
six to seven different sites from each of these areas analyzed to
determine the degree of pulmonary injury, extent and composi-
tion of immune cellular inﬁltrate, anatomy of the alveolar air sac
and the presence or absence of exudate into the alveolar sac. As
seen in Figs. 2 and 3, ferrets treated with vehicle (S1P1Rnil oselnil)
showed massive pulmonary injury in terms of pulmonary tissue
consolidation, exudates in the alveolar air sacs, thickening of
alveolar walls, and massive interstitial and intra-alveolar inﬂam-
matory inﬁltrates when compared to similarly infected ferrets
receiving either RP-002 alone (S1P1Rþ oselnil) or oseltamivir alone
(S1P1Rnil oselþ). Minimal injury was recorded in ferrets receiving
both therapies combined (S1P1Rþ oselþ). Utilizing a score of
0–1¼o10% lung involvement; 1–2¼10–30% lung involvement;
23¼30–60% lung involvement; 3–4¼460% lung involvement,
we evaluated six to seven separate random ﬁelds per tissue
section from the portions of right and left upper, middle, and
lower lobes.
The differences found were highly signiﬁcant (Po0.0001)
when comparing ferrets using vehicle only to those treated with
either S1P1 receptor agonist or oseltamivir only or to ferrets
receiving a combination of both therapies. Ferrets treated with
RP-002 displayed signiﬁcantly less pulmonary injury than ferrets
treated with oseltamivir alone (Po0.001). However, by far, ferrets
that received a combination of both drugs showed the least degree
of pulmonary injury (Po0.0001) when compared to the other
groups of treated ferrets.
Fig. 3 displays higher resolution microscopy of representative
pulmonary tissue from each of the four ferret groups. The upper
panel for ferrets only receiving vehicle (S1P1Rnil oselnil) showed
exudates that obstruct alveolar sacs and massive thickening of the
alveolar walls, while the lower panel showed considerable inﬂam-
matory cells in interstitial pulmonary tissue and in the air sac
spaces. Ferrets treated with only S1P1R agonist or only with
oseltamivir displayed more open alveolar air spaces and fewer
inﬂammatory inﬁltrates than vehicle treated ferrets, although
inﬂammation in oseltamivir treated ferrets was greater than in
the S1P1 agonist treated ferrets. Inﬂammatory inﬁltrates consisted
primarily of polymorphonuclear cells, but also abundant mono-
cytes/lymphocytes with occasional histiocytes and fewer plasma
cells. By contrast, ferrets receiving combined S1P1R agonist RP-
002 and oseltamivir therapy portrayed the most abundant open
Fig. 1. Combined RP-002 S1P1R agonist and oseltamivir therapy, RP-002 or
oseltamivir alone blunt the clinical manifestation of disease in ferrets following
infection with 1106 TCID50 dose of A/California/09/04H1N1 given intranasally.
Four ferrets in each group tested. Panel A: Temperatures recorded daily at two sites
(shoulder blade and hip). Data plotted as degree of temperature change from
baseline level of ferrets prior to initiation of infection or therapies. Panel B: Daily
activity recorded twice daily as alert and playful, alert and playful only when
stimulated, or neither alert or playful at any time. Bar graphs record percent of
ferrets in each group that display activity (100%) to those showing no activity (0%).
Panel C plots weight changes from the baseline measurement of each group prior
to infection and thereafter during the course of infection with the various
therapeutic treatments. Ferrets in each group followed for 12 days.
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and anatomically normal alveolar air spaces along with the fewest
number of inﬂammatory cells.
The last series of studies measured levels of inﬂuenza virus RNA
from ferret lung samples from all treatment groups on day 3 post-
infection. Using uninfected ferret lung RNA as a baseline, we
observed signiﬁcant levels of inﬂuenza virus RNA in the lungs of
vehicle treated ferrets (Fig. 4). Similar to our previous results,
treatment with S1P1R agonist did not signiﬁcantly affect the levels
of viral RNA detected on day 3 post-infection (Fig. 4). Further, in
agreement with the antiviral activity of oseltamivir, we observed
signiﬁcant (42 log) reductions in viral RNA in the lungs of ferrets
treated with either oseltamivir alone or combined RP-002 and
oseltamivir (Fig. 4). Taken together, our results demonstrate that
the S1P1R agonist, RP-002, can alleviate clinical symptoms and
lung pathology independent of virus replication. However, max-
imal protection occurs with combined therapy blunting both
immune pathology and suppressing viral replication.
In summary, this paper documents in a second animal model,
the ferret, the applicability of S1P1 receptor agonist in blunting
disease caused by a human pathologic H1N1 infection. This blunting
is reﬂected in the S1P1 receptor agonist ability to down-regulate
and control the massive innate inﬂammatory response despite
minimally altering viral replication. Attempts to biochemically
measure cytokine/chemokine message or molecules associated with
cytokine storm was unsuccessful because of poor test reproduci-
bility due to the unreliability of reagents and assays currently in use
for the ferret. A weakness of the ferret model at present is the
absence of ferret reagents required to give robust reproducible
results required to quantitate these inﬂammatory molecules.
In conclusion, the major advantage of the ferret model is
its close relationship to the clinical course and the respiratory
architecture and physiology of humans for study of human
inﬂuenza virus infection. Using the ferret model we showed
here the utility of S1P1 receptor agonist as a potential therapy
Fig. 2. Histopathologic analysis of pulmonary tissues on day 3 post-inﬂuenza infection revealed signiﬁcantly less injury in ferrets receiving both S1P1R and oseltamivir
therapy than in ferrets receiving either treatment separately. Tissue injury was signiﬁcantly less in ferrets receiving only the S1P1R agonist when compared to ferrets treated
with oseltamivir. Ferrets receiving combined S1P1R agonist and oseltamivir therapy showed diminished polymorphonuclear cells, mononuclear cells, histiocyte and plasma
cell inﬁltrates in interstitial tissues and intra-alveolar spaces, negligible exudates in alveolar air spaces and minimal alveolar wall thickening than displayed in ferrets in the
other three groups. Vehicle only (S1P1Rnil oselnil) treated ferrets, by contrast, portrayed massive lung consolidation, exudate in alveolar air space, thickening of alveolar walls,
vascular hemorrhage and excessive interstitial and intra-alveolar inﬂammatory inﬁltrates. Four ferrets comprised each group with samples obtained from right and left
upper, middle, and lower lobes. Tissue inﬂammatory score numbers (path index) are derived from the mean lung involvement of at least six random ﬁelds per tissue section
for each lung lobe sampleþSEM. Numbers correspond: 0–1¼r10% or less lung involvement; 1–2¼10–30% lung involvement; 2–3¼30–60% lung involvement; 3–4¼Z60%
lung involvement. Magniﬁcation 200 with scale bars of 100 mm shown. P values comparing each of the three treatment groups to the non-treatment groups was
Po0.0001. Signiﬁcance (Po0.0001) occurred between ferrets receiving combined S1P1Rþ oselþ therapy vs. either vehicle, S1P1Rþ oselnil or S1P1Rnil oselþ , and S1P1Rþ
oselnil or S1P1Rnil oselþ compared to vehicle. Pulmonary injury score was signiﬁcantly better in ferrets receiving S1P1Rþ only compared to those only receiving oseltamivir
(P¼0.001).
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combined with administration of an antiviral drug to successfully
treat pathogenic human inﬂuenza and established that such
ﬁndings in the ferret closely mimicked our previous studies in
the mouse (Teijaro et al., 2011; Walsh et al., 2011). Injury and
disease resulting from inﬂuenza virus infection depends on two
separate but intertwined components, the virus infection itself
which can be blunted by antiviral therapy and excessive inﬂam-
matory immune response that can be controlled by the immuno-
modulating S1P1R agonist molecule. Thus, both the mouse and
ferret model demonstrated the importance of utilizing combined
antiviral oseltamivir and S1P1 receptor agonist therapy for optimal
results in treatment of pathogenic human H1N1 swine inﬂuenza
infection. Cytokine storm plays a prominent and commanding role
in other acute severe respiratory disorders like hantavirus
(Macneil et al., 2011), SARS (Thiel and Weber, 2008), respiratory
syncytial viral infection (Kawashima et al., 2012), and other
respiratory viral infections suggesting the potential utility of S1P
agonist immunomodulatory therapy to inhibit the excessive and
disorganized immune responses in these illnesses.
Materials and methods
Virus and infection
Inﬂuenza virus A/California/04/2009 was ampliﬁed and plaqued
on Madin–Darby canine kidney (MDCK) cells. Inﬂuenza infection
was performed in a BSL-3 biocontainment facility at Battelle Labs.
Inﬂuenza virus was inoculated via the intranasal route following
Telazal anesthesia (16–22 mg/kg via intramuscular injection).
1106 plaque forming units (PFU) in 600 ml of phosphate buffered
saline (PBS) was introduced slowly into the nasal cavity of ferrets by
four 150 m aliquots inoculated alternatively in each nostril.
Viral RNA quantiﬁcation
Inﬂuenza A/California/04/2009 viral RNA was measured using
the standard real-time RT-PCR assay for detection of the inﬂuenza
A virus matrix gene from the World Health Organization0s manual
for molecular diagnosis of inﬂuenza virus in humans, annex
2 protocol 1. For the real time PCR reaction, cDNA was made from
RNA isolated from ferret lung tissue. We used 100 ng of cDNA from
lung tissue for each reaction. As a standard we puriﬁed viral RNA
from cellular supernatants of stock virus with a known titer
Fig. 3. Higher resolution analysis of representative samples displayed in Fig. 2. Magniﬁcation 400 with scale bars of 100 mm, or 600 with scale bars of 50 mm.
Fig. 4. Viral loads of A/California/09/04H1N1 on day 3 post-infection in ferrets
treated with either vehicle, RP-002, oseltamivir or combined RP-002 and oselta-
mivir. Data are presented as fold increase over uninfected ferret lung tissue and are
representative of four individual ferrets. nnpo0.01, npo0.05 as determined by two-
tailed student t-test.
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(6106 PFU/mL) using the Qiagen RNeasy mini kit and made
cDNA and 10-fold serial dilutions using no cDNA as a negative
control. Viral RNA quantities for the vehicle control were in the
range of 102–103 PFU/100 ng cDNA based on our standard.
Drug treatment
Ferrets were treated with the S1P1 receptor-selective agonist
RP-002 dissolved in water by oral gavage at a dose of 6 mg/kg/day
on days 0, 1 and 2 post-infection. The selectivity, characterization,
and synthesis of RP-002 were described by Teijaro et al. (2011).
Control ferrets received the same volume of water by oral gavage.
Oseltamivir was dissolved in water to a ﬁnal concentration of
12 mg/mL. Oseltamivir (25 mg/kg/day) was administered to ferrets
1 h post-infection and on days 1–5 post-infection twice per day
(12.5 mg/kg/dose).
Ferret monitoring
Thirty-ﬁve neutered and de-scented male ferrets were pur-
chased from Triple F Farms for this study. Prior to infection ferrets
were determined to be in good health and were seronegative
for A/California/4/09 (H1N1), A/Perth/16/2009 (H3N2) and B/
Brisbane/60/2008/. Ferrets were weighed on days 1 and 0. Body
weight from day 0 served as the baseline. Ferrets were weighed
daily throughout the study until sacriﬁce. For body temperature
measurements, anesthetized ferrets were recorded from implants
in the shoulder and rump area. Temperatures were taken on days
2, 1 and 0 pre-infection and temperatures averaged from 2,
1 and 0 to serve as the baseline reading. Temperature readings
were taken daily from both transponders, average taken from both
sites and compared to the baseline reading until the end of the
experiment.
Observations: observations were taken twice daily upon arrival
of ferrets prior to infection. Following challenge, observations
were made twice daily until the end of the experiment and were
done blind by an independent observer. The following scoring
system was used: 0 – alert and playful, 1 – alert but playful only
when stimulated, 2 – alert but not playful when stimulated, and
3 – neither alert or playful when stimulated.
Tissue sample collection and processing
All animals had a gross necropsy performed on the day of
sacriﬁce. Ferrets were euthanized by ﬁrst sedating with Telazol
followed by a euthanasia solution approved by the American
Veterinary Medical Association (AVMA). Lungs were collected
and processed into 1 cm3 portion from three right lung lobes.
Three complete sets of three were collected and one set stored
in 10% neutral buffered formalin. A second set was snap frozen
in a dry ice/alcohol bath. The ﬁnal set of tubes was placed in
pre-weighed tubes containing RNAlater. All samples were frozen
at 70 1C. Lungs were blocked in parafﬁn, and 10 μm tissue
sections were cut from each section of the ferret lung, placed on
glass slides, and stained with hematoxylin and eosin.
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